Analysts Set GeoVax Labs, Inc. (NASDAQ:GOVX) PT at $14.20

GeoVax Labs, Inc. (NASDAQ:GOVX) has earned a consensus rating of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $14.20.

Several equities analysts have commented on GOVX shares. Noble Financial raised their target price on shares of GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a report on Monday, August 19th. D. Boral Capital reiterated a “buy” rating and set a $18.00 price target on shares of GeoVax Labs in a research report on Tuesday, November 19th. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a research report on Friday, November 15th. Finally, Alliance Global Partners began coverage on GeoVax Labs in a report on Monday, November 11th. They issued a “buy” rating and a $15.00 target price on the stock.

Institutional Investors Weigh In On GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Virtu Financial LLC purchased a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned about 0.43% of GeoVax Labs as of its most recent filing with the Securities & Exchange Commission. 6.09% of the stock is owned by hedge funds and other institutional investors.

GeoVax Labs Trading Up 15.1 %

NASDAQ GOVX opened at $2.52 on Friday. GeoVax Labs has a 1-year low of $1.09 and a 1-year high of $11.18. The company has a 50 day moving average of $2.31 and a 200-day moving average of $2.72.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.38. The company had revenue of $2.79 million during the quarter, compared to analyst estimates of $1.84 million. During the same period in the prior year, the firm earned ($4.80) earnings per share. Sell-side analysts expect that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.